LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System鈩�; Findings Increase Average in Natural GLP-1 Production to Over 200%鈥♀赌�
LifeVantage (Nasdaq: LFVN) has announced expanded clinical trial results for its MindBody GLP-1 System鈩�, showing enhanced effectiveness in natural GLP-1 production. The combined data from trials completed in April 2025 and fall 2024 demonstrated an average increase in GLP-1 of over 200%, up from the previously reported 140%.
The clinical studies revealed significant outcomes including average weight loss of 11 pounds within 12 weeks, with some participants losing up to 25 pounds. Key body composition improvements include up to 9% decrease in total body fat, 24% decrease in visceral fat, and 6% increase in skeletal muscle. Notably, 100% of weight lost was from fat, not muscle.
Participants reported substantial behavioral changes, with 95% experiencing decreased sugar cravings and over 85% reporting improved eating habits and reduced hunger. The company also completed an independent 12-week trial of the international formula (MB System) with similar positive results.
LifeVantage (Nasdaq: LFVN) ha annunciato risultati ampliati degli studi clinici per il suo MindBody GLP-1 System鈩�, evidenziando una maggiore efficacia nella produzione naturale di GLP-1. I dati combinati degli studi completati nell'aprile 2025 e nell'autunno 2024 hanno mostrato un aumento medio del GLP-1 superiore al 200%, rispetto al 140% precedentemente riportato.
Gli studi clinici hanno rivelato risultati significativi, tra cui una perdita di peso media di 11 libbre in 12 settimane, con alcuni partecipanti che hanno perso fino a 25 libbre. I miglioramenti chiave nella composizione corporea includono una riduzione fino al 9% del grasso corporeo totale, una diminuzione del 24% del grasso viscerale e un aumento del 6% della massa muscolare scheletrica. Da notare che il 100% del peso perso proveniva dal grasso e non dalla massa muscolare.
I partecipanti hanno riportato cambiamenti comportamentali significativi, con il 95% che ha sperimentato una diminuzione delle voglie di zucchero e oltre l'85% che ha riferito un miglioramento nelle abitudini alimentari e una riduzione della fame. L'azienda ha inoltre completato uno studio indipendente di 12 settimane sulla formula internazionale (MB System) con risultati positivi simili.
LifeVantage (Nasdaq: LFVN) ha anunciado resultados ampliados de ensayos cl铆nicos para su MindBody GLP-1 System鈩�, mostrando una mayor efectividad en la producci贸n natural de GLP-1. Los datos combinados de los ensayos completados en abril de 2025 y oto帽o de 2024 demostraron un aumento promedio en GLP-1 de m谩s del 200%, frente al 140% reportado anteriormente.
Los estudios cl铆nicos revelaron resultados significativos, incluyendo una p茅rdida de peso promedio de 11 libras en 12 semanas, con algunos participantes perdiendo hasta 25 libras. Las mejoras clave en la composici贸n corporal incluyen hasta un 9% de disminuci贸n en la grasa corporal total, una reducci贸n del 24% en la grasa visceral y un aumento del 6% en la masa muscular esquel茅tica. Es importante destacar que el 100% del peso perdido fue grasa, no m煤sculo.
Los participantes reportaron cambios conductuales sustanciales, con un 95% experimentando una disminuci贸n en los antojos de az煤car y m谩s del 85% reportando mejores h谩bitos alimenticios y reducci贸n del hambre. La compa帽铆a tambi茅n complet贸 un ensayo independiente de 12 semanas de la f贸rmula internacional (MB System) con resultados positivos similares.
LifeVantage (雮橃姢雼�: LFVN)电� MindBody GLP-1 System鈩�鞚� 鞛勳儊 鞁滍棙 瓴瓣臣毳� 頇曥灔 氚滍憸頃橂┌ 鞛愳棸鞝侅澑 GLP-1 靸濎偘 須姤鞚� 頄レ儊霅橃棃鞚岇潉 氤挫榾鞀惦媹雼�. 2025雲� 4鞗旉臣 2024雲� 臧�鞚勳棎 鞕勲霅� 鞁滍棙霌れ潣 瓴绊暕 雿办澊韯暗鐢 鞚挫爠鞐� 氤搓碃霅� 140%鞐愳劀 韽夑窢 GLP-1 歃濌皜鞙澊 200% 鞚挫儊鞛勳潉 雮橅儉雰堨姷雼堧嫟.
鞛勳儊 鞐瓣惮鞐愳劀电� 12欤� 雮挫棎 韽夑窢 11韺岇毚霌� 觳挫 臧愳唽臧� 鞛堨棃鞙茧┌, 鞚茧秬 彀戈皜鞛惖鐢 斓滊寑 25韺岇毚霌滉箤歆� 臧愲焿頄堨姷雼堧嫟. 欤检殧 觳挫劚攵� 臧滌劆鞚� 齑� 觳挫氚� 斓滊寑 9% 臧愳唽, 雮挫灔 歆�氚� 24% 臧愳唽, 瓿博攴茧焿 6% 歃濌皜毳� 韽暔頃╇媹雼�. 韸鬼瀳, 臧愲焿霅� 觳挫鞚� 100%臧� 歆�氚╈棎靹� 雮橃槰 瓴冹澊 頇曥澑霅橃棃鞀惦媹雼�.
彀戈皜鞛愲摛鞚� 頄夒彊 氤�頇旊弰 韥矊 氤搓碃頄堨溂氅�, 95%臧� 靹ろ儠鞐� 雽�頃� 臧堧 臧愳唽毳� 瓴巾棙頄堦碃 85% 鞚挫儊鞚� 鞁濎姷甏� 臧滌劆瓿� 項堦赴 臧愳唽毳� 氤搓碃頄堨姷雼堧嫟. 須岇偓电� 霕愴暅 甑牅 瓿奠嫕(MB System)鞐� 雽�頃� 霃呺鞝侅澑 12欤� 鞁滍棙鞚� 鞕勲頄堨溂氅� 鞙犾偓頃� 旮嶌爼鞝� 瓴瓣臣毳� 鞏混棃鞀惦媹雼�.
LifeVantage (Nasdaq : LFVN) a annonc茅 des r茅sultats 茅tendus d'essais cliniques pour son MindBody GLP-1 System鈩�, d茅montrant une efficacit茅 accrue dans la production naturelle de GLP-1. Les donn茅es combin茅es des essais r茅alis茅s en avril 2025 et 脿 l'automne 2024 ont montr茅 une augmentation moyenne du GLP-1 de plus de 200%, contre 140% pr茅c茅demment rapport茅s.
Les 茅tudes cliniques ont r茅v茅l茅 des r茅sultats significatifs, notamment une perte de poids moyenne de 11 livres en 12 semaines, certains participants ayant perdu jusqu'脿 25 livres. Les am茅liorations cl茅s de la composition corporelle incluent une r茅duction jusqu'脿 9% de la masse grasse totale, une diminution de 24% de la graisse visc茅rale et une augmentation de 6% de la masse musculaire squelettique. Il est 脿 noter que 100% du poids perdu provenait de la graisse et non du muscle.
Les participants ont rapport茅 des changements comportementaux importants, avec 95% ayant ressenti une diminution des envies de sucre et plus de 85% signalant une am茅lioration des habitudes alimentaires et une r茅duction de la faim. L'entreprise a 茅galement men茅 un essai ind茅pendant de 12 semaines sur la formule internationale (MB System) avec des r茅sultats positifs similaires.
LifeVantage (Nasdaq: LFVN) hat erweiterte klinische Studienergebnisse f眉r sein MindBody GLP-1 System鈩� bekannt gegeben, die eine verbesserte Wirksamkeit bei der nat眉rlichen GLP-1-Produktion zeigen. Die kombinierten Daten aus Studien, die im April 2025 und Herbst 2024 abgeschlossen wurden, zeigten eine durchschnittliche Steigerung des GLP-1 um 眉ber 200%, im Vergleich zu zuvor berichteten 140%.
Die klinischen Studien ergaben signifikante Ergebnisse, darunter einen durchschnittlichen Gewichtsverlust von 11 Pfund innerhalb von 12 Wochen, wobei einige Teilnehmer bis zu 25 Pfund abnahmen. Wichtige Verbesserungen der K枚rperzusammensetzung umfassen eine Reduktion des K枚rperfetts um bis zu 9%, eine Abnahme des viszeralen Fetts um 24% und eine Zunahme der Skelettmuskulatur um 6%. Bemerkenswert ist, dass 100% des verlorenen Gewichts Fett und kein Muskel war.
Die Teilnehmer berichteten von erheblichen Verhaltens盲nderungen, wobei 95% eine Verringerung des Zuckerverlangens erlebten und 眉ber 85% verbesserte Essgewohnheiten und reduzierten Hunger angaben. Das Unternehmen schloss zudem eine unabh盲ngige 12-w枚chige Studie mit der internationalen Formel (MB System) mit 盲hnlichen positiven Ergebnissen ab.
- Clinical trials showed over 200% increase in natural GLP-1 production, significantly higher than previous 140% result
- Average weight loss of 11 pounds in 12 weeks, with some participants losing up to 25 pounds
- Strong body composition improvements including 9% decrease in body fat and 6% increase in skeletal muscle
- High efficacy rates with 95% of participants reporting decreased sugar cravings
- Successful validation of both U.S. and international formulas through independent clinical trials
- None.
Insights
LifeVantage reports impressive clinical results for its natural GLP-1 stimulator, showing 200% hormone increase and significant weight management outcomes without pharmaceuticals.
LifeVantage has released compelling expanded clinical data for its MindBody GLP-1 System鈩�, showing the natural supplement now achieves an average
The expanded trials revealed participants lost an average of 11 pounds within 12 weeks, with some losing up to 25 pounds. Crucially, body composition metrics showed that
Beyond physical metrics, the behavioral data is particularly noteworthy, with
By focusing on natural GLP-1 stimulation rather than exogenous GLP-1 administration (like Ozempic or Wegovy), LifeVantage is targeting consumers seeking non-pharmaceutical alternatives in the metabolic health space. The company's approach leverages the body's endogenous hormone production systems, potentially offering fewer side effects than injectable GLP-1 agonists while addressing the same biological pathways that regulate appetite and metabolism.
The international formula study results provide validation for global market expansion, suggesting the company has addressed regional regulatory requirements while maintaining efficacy across different populations.
Expanded U.S.-clinical research study shows strong results including increased fat loss, improved cravings control, and healthier body composition*鈥�
SALT LAKE CITY, July 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new results from its second human clinical study on the , revealing even more compelling outcomes across a broader participant base.
When researchers combined data from the most recent clinical trial completed in April 2025, with findings from the initial trial conducted in fall 2024, the average increase of GLP-1 improved to over
鈥淭hese findings validate the effectiveness of our natural approach to stimulating the body鈥檚 own production of GLP-1 and other key metabolic hormones,鈥� said Lisa Barnes, Vice President of R&D and Regulatory at LifeVantage. 鈥淭he MindBody GLP-1 System and living an activated lifestyle produces meaningful, lasting results 鈥� helping people manage cravings, improve self-control, and support sustainable metabolic health naturally. We remain committed to delivering evidence-based innovations that empower health from within.*鈥�
Key findings from LifeVantage鈥檚 U.S. clinical studies on the MindBody GLP-1 System include:
- Over
200% average increase in GLP-1 over 12 weeks鈥♀赌� - Average weight loss of 11 pounds within 12 weeks, with some participants losing up to 25 pounds鈥�,鈥�鈥�
- Up to
9% decrease in total body fat percentage聽鈥�,鈥�鈥� - Up to
24% decrease in visceral fat鈥�,鈥�鈥� - Up to
9% decrease in subcutaneous fat鈥�,鈥�鈥� - Up to
6% increase in skeletal muscle鈥♀赌� 100% of weight lost was from fat, not muscle鈥�,惟惟
In addition to these physical results, participants reported notable changes in their relationship with food:
95% reported decreased sugar cravings惟惟89% reported decreased fast-food cravings搂搂86% reported decreased cravings for salt and soda搂搂85% now eat for health instead of emotions惟惟81% reported increased ability to resist snacking搂搂89% ate less at meals搂搂86% reported feeling less hungry搂搂
Additionally, LifeVantage completed an independent 12-week human clinical trial of the international formula, known as the MB System, affirming the Company鈥檚 commitment to science-backed innovation across global markets. The study was conducted by Lighthouse Research and demonstrated an average increase in GLP-1 production of over
To learn more about the clinical trial findings or explore how the MindBody GLP-1 System can fit into your wellness routine, visit www.lifevantage.com.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics鈥攖he study of how nutrition and naturally occurring compounds can unlock your genes, and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim庐 family of products, TrueScience庐 Liquid Collagen, the newest MindBody GLP-1 System鈩�, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System庐, as well as AXIO庐 nootropic energy drink mixes, the full TrueScience庐 line of skin and hair care products, and Petandim庐, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit
鈥♀赌� Results based on the averaged data of two 12-week randomized human clinical studies.
惟惟 Results based on a randomized 12-week human clinical study (Study A, N=56).
搂搂 Results based on a randomized 12-week human clinical study (Study B, N=107).
鈥÷燫esults may vary. Typical weight loss using this product in a 12-week weight management program is 1鈥�2 pounds per week. This product should be used in conjunction with a healthy diet and regular exercise. Consult with a healthcare provider before starting any weight loss program.聽
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Public Relations Contact:
CerconeBrownCompany
[email protected]
Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
[email protected]
FAQ
What are the latest clinical trial results for LifeVantage's (LFVN) MindBody GLP-1 System?
How effective is LifeVantage's MindBody GLP-1 System for weight loss?
What percentage of body fat reduction did LFVN's GLP-1 System achieve in clinical trials?
How does LifeVantage's MindBody GLP-1 System affect food cravings?
What behavioral changes were reported in LFVN's GLP-1 System clinical trials?
